Sanara MedTech Stock: Fair Value
SMTIThe fair value of Sanara MedTech under our model is $36.27, the price is 10% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 20 Nov 2026
Valuation Signal
Fairly valuedIn our model the price counts as cheap below $25.91 and expensive above $60.46 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $29.75, at 7.8% it would be $46.10.
Where the Number Comes From
From the cash-flow model alone; without earnings there is no industry value.
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 3.8%. Discounted at 8.8% (floor: government bond yield 3.8% plus 5 percentage points, since beta 0.87 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe Calculation Step by Step
With these figures the cash flow model arrives at $36.27 per share: free cash flow for the next ten years, each year discounted to today at 8.8%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 8.8%) |
|---|---|---|---|---|
| 2026 | $7.44M | extrapolated at 46.5% | 0.9189 | $6.84M |
| 2027 | $9.95M | extrapolated at 33.7% | 0.8443 | $8.4M |
| 2028 | $12.41M | extrapolated at 24.7% | 0.7758 | $9.63M |
| 2029 | $14.71M | extrapolated at 18.5% | 0.7129 | $10.48M |
| 2030 | $16.78M | extrapolated at 14.1% | 0.6550 | $10.99M |
| 2031 | $18.62M | extrapolated at 11.0% | 0.6019 | $11.21M |
| 2032 | $20.27M | extrapolated at 8.9% | 0.5530 | $11.21M |
| 2033 | $21.76M | extrapolated at 7.3% | 0.5082 | $11.06M |
| 2034 | $23.13M | extrapolated at 6.3% | 0.4669 | $10.8M |
| 2035 | $24.41M | extrapolated at 5.6% | 0.4291 | $10.47M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $101.09M |
| Terminal value: cash flow 2035 × (1 + 3.8%) / (8.8% − 3.8%) | $506.95M |
| Present value of terminal value (× 0.4291) | $217.51M |
| Equity value (sum plus present value of terminal value) | $318.61M |
| Shares (diluted) | 8.78M |
| Value per share (equity value divided by shares) | $36.27 |
| Fair value (from the cash flow model alone) | $36.27 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
